Post by account_disabled on Dec 30, 2023 10:24:13 GMT
Bioeq's agreement will bring biosimilar to Lucentis(R), the company's lead product for treating retinopathy. One step closer to patients in the United States - Bioeq IP AG ("Bioeq") today announced that The Company has entered into a license and development agreement with Coherus BioSciences, Inc. ("Coherus" Nasdaq:CHRS), under which Coherus will market and distribute Lucentis(R) (ranibizumab), a biosimilar of Lucentis(R) (ranibizumab). Bioeq exclusive in the USA Bioeq will continue to be responsible for filing the Biologics License Application (BLA) with the U.S. Food and Drug Administration in Q4 and will be responsible for commercializing the product next.
Coherus plans to launch B2B Email List the product. In 2021 Commenting on the agreement, Hannes Teissl, Bioeq Board Member, said: “We are proud to have Coherus as our U.S. partner. This agreement marks an important milestone in providing a highly effective yet affordable alternative to retinal treatments. This includes age-related macular degeneration. for patients in the United States" According to the terms of the agreement, Bioeq will receive an upfront payment. Regulatory payments and payment upon product launch Including shared profits “Starting in 2020, Bioeq will be in a position to license ranibizumab biosimilars to marketing and distribution partners outside the US,” said Bioeq Board Member Nicola Mikulcik.
Notes for editors Lucentis(R) is a registered trademark of Genentech, Inc. Lucentis(R) is a biopharmaceutical containing the monoclonal antibody ranibizumab, which is approved for the treatment of ophthalmology. Such as age-related macular degeneration. Wet macular degeneration (neovascular) Retinal swelling after retinal vein occlusion. Retinal swelling from diabetes and diabetic retinopathy. In the United States, annual sales of Lucentis(R) are approximately $1.8 billion [1]. Biosimilar medicines It is intended to replace existing branded biologics. To treat chronic and life-threatening diseases It has the potential to reduce costs and expand access for patients. These biosimilars exhibit analytical and clinical characteristics similar to the branded reference product.
Coherus plans to launch B2B Email List the product. In 2021 Commenting on the agreement, Hannes Teissl, Bioeq Board Member, said: “We are proud to have Coherus as our U.S. partner. This agreement marks an important milestone in providing a highly effective yet affordable alternative to retinal treatments. This includes age-related macular degeneration. for patients in the United States" According to the terms of the agreement, Bioeq will receive an upfront payment. Regulatory payments and payment upon product launch Including shared profits “Starting in 2020, Bioeq will be in a position to license ranibizumab biosimilars to marketing and distribution partners outside the US,” said Bioeq Board Member Nicola Mikulcik.
Notes for editors Lucentis(R) is a registered trademark of Genentech, Inc. Lucentis(R) is a biopharmaceutical containing the monoclonal antibody ranibizumab, which is approved for the treatment of ophthalmology. Such as age-related macular degeneration. Wet macular degeneration (neovascular) Retinal swelling after retinal vein occlusion. Retinal swelling from diabetes and diabetic retinopathy. In the United States, annual sales of Lucentis(R) are approximately $1.8 billion [1]. Biosimilar medicines It is intended to replace existing branded biologics. To treat chronic and life-threatening diseases It has the potential to reduce costs and expand access for patients. These biosimilars exhibit analytical and clinical characteristics similar to the branded reference product.